Clinical trial · Interventional
A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC
A Translational Study of Tumor Antigen-pulsed Dendritic Cell Vaccine for Esophageal Squamous Cell Carcinoma
NCT05317325CI-TRIAL-00057641unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-pulsed DC vaccine( OCDC and NeoDC) for postoperative adjuvant treatment of ESCC
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| OCDC vaccine; NeoDC vaccine | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Experimental Group
- description
- Autologous DCs pulsed with HOCl-oxidized autologous tumor lysate (OCDC) vaccine is administered in prime phase and personal neoantigen-sensitized DC(NeoDC) vaccine is administered in boost phase.
- interventionNames
- Biological: OCDC vaccine; NeoDC vaccine
Primary outcomes (1)
- measure
- The number of treatment-related adverse events
- timeFrame
- From the first administration of vaccine to 3 months after the last administration
- description
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Secondary outcomes (1)
- measure
- Disease-free Survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed diagnosis of esophageal squamous cell carcinoma * no preoperative adjuvant therapy * Karnofsky performance status 0-2; * The postoperative pathological stage is pT2-4 and / or N + M0 according to AJCC 8th * Function of the main organs is normal; * Edition Patient's written informed consent Exclusion Criteria: * Tumor emergencies; * Abnormal coagulation function; * Contagious diseases, such as HIV, HBV, HCV infection; * Mental disorders; * Concomitant tumors; * Immunological co-morbidities
References
Publications (0)
Data not yet available
No reference posted for this study.